DEINOVE CONFIRMS ITS FINANCING OPTIONS BY RENEWING ITS EQUITY LINE

This new program gives DEINOVE additional financial flexibility particularly in light of the upcoming start of the Phase IIa clinical trial of its antibiotic candidate, DNV3837.

November 21, 2018
DEINOBIOTICS/DEINOVE

Montpellier, November 21th, 2018 (7:00 am CET) – DEINOVE (Euronext Growth Paris : ALDEI), a biotech company that discovers, develops and produces high value-added compounds based on rare bacteria, announces the set-up of a new equity line with KEPLER CHEUVREUX for a maximum amount of €12 million over 36 months.

Press release available here: